DelistingJun 9, 2026, 04:12 PM
Jasper Therapeutics Receives Nasdaq Delisting Notice for Low Bid Price
AI Summary
Jasper Therapeutics, Inc. received a notice from The Nasdaq Stock Market LLC on June 3, 2026, indicating non-compliance with the minimum $1.00 bid price requirement for continued listing. The company's voting common stock had closed below $1.00 per share for 30 consecutive business days. Jasper Therapeutics has an initial 180-calendar day period, until November 30, 2026, to regain compliance. The company intends to monitor its bid price and consider options, including a reverse stock split, if necessary.
Key Highlights
- Jasper Therapeutics received a Nasdaq notice on June 3, 2026, for non-compliance with the $1.00 minimum bid price rule.
- The company's common stock bid price closed below $1.00 for 30 consecutive business days.
- Jasper Therapeutics has an initial 180-calendar day period, until November 30, 2026, to regain compliance.
- To regain compliance, the bid price must close at $1.00 or more for a minimum of ten consecutive business days.
- The notice has no immediate effect on the listing or trading of the company's stock or warrants.
- The company may consider options including a reverse stock split to regain compliance.
Price Impact
More from JSPR